Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease

Filippo Alongi, Stefano Arcangeli, Luca Triggiani, Rosario Mazzola, Michela Buglione di Monale e Bastia, Sergio Fersino, Anna Baiguini, Barbara Alicja Jereczek-Fossa, Stefano Maria Magrini, on the behalf of Italian Association of Radiation Oncology [AIRO]

Research output: Contribution to journalReview articlepeer-review

Abstract

Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.

Original languageEnglish
Pages (from-to)48-56
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume117
DOIs
Publication statusPublished - Sep 1 2017

Keywords

  • Oligometastases
  • Renal cell carcinoma
  • SABR
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Fingerprint

Dive into the research topics of 'Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease'. Together they form a unique fingerprint.

Cite this